The development of systemic sclerosis classification criteria

Clinical Rheumatology

Volumn 26, Issue 9, 2007, Pages 1401-1409

  Walker, Jennifer G ^a   Pope, Janet ^b   Baron, Murray ^c   LeClercq, Sharon ^a   Hudson, Marie ^c   Taillefer, Suzanne ^c   Edworthy, Steven M ^a   Nadashkevich, Oleg ^d   Fritzler, Marvin J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Autoantibodies; Classification; Nailfold capillaroscopy; Review; Scleroderma; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III;

ANTIBODY DETECTION; CAPILLAROSCOPY; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE REGISTRY; ENDOTHELIAL DYSFUNCTION; EOSINOPHILIC FASCIITIS; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LUNG FIBROSIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; RHEUMATOLOGY; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SKIN FIBROSIS; SKINFOLD; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VALIDATION PROCESS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; MICROSCOPIC ANGIOSCOPY; SCLERODERMA, SYSTEMIC;

EID: 34547576493     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0537-x     Document Type: Review

References (48)

1. Tan FK (2003) Systemic sclerosis: The susceptible host (genetics and environment). Rheum Dis Clin North Am 29:211-237
2. Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y (2005) New therapeutic strategies for systemic sclerosis - a critical analysis of the literature. Clin Dev Immunol 12(3):165-173
3. Mayes MD, Giannini EH, Pachman LM et al (1997) Connective tissue disease registries. Arthritis Rheum 40:1556-1559
4. Barnett AJ, Miller MH, Littlejohn GO (1988) A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 15(2):276-283 (Feb)
5. Maricq HR, Valter I (2004) A working classification of scleroderma spectrum disorders: A proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 22(3 Suppl 33):S5-S13 (Jan-Feb)
6. Steen VD, Oddis CV, Conte CG et al (1997) Incidence of systemic sclerosis in Allegheny county, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 40(3):441-445
7. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573-1576
8. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581-590
9. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15(2):202-205 (Feb)
10. Nadashkevich N, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10(11):CR615-CR621
11. Fries JF, Hochberg MC, Medsger TA Jr et al (1994) Criteria for rheumatic disease. Different types and different functions. Arthritis Rheum 37(4):454-462
12. Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis. Arthritis Rheum 52(4):1000-1008
13. Classification and response criteria subcommittee of the American College of Rheumatology Committee on Quality Measures (2006) Development of classification and response criteria for rheumatic diseases. Arthritis Rheum (Arthritis Care and Research) 55(3):348-352
14. Felson DT, Anderson JJ (1995) Methodological and statistical approaches to criteria development in rheumatic diseases. Bailliere's Clin Rheumatol 9:253-266
15. Maricq HR, Weinrich MC, Keil JE et al (1989) Prevalence of the scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 32(8):998-1006
16. Steen V, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437-2444
17. Steen V, Medsger TA Jr (2001) Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 44(12):2828-2835
18. Giordano M, Valentini G, Migliaresi S et al (1986) Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13:911-916
19. Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 81(2):139-153
20. Scussel-Lonzetti L, Joyal F, Raynauld JP et al (2002) Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 81(2):154-167
21. Tuffanelli DL, Winkelmann RK (1962) Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 57:198-203
22. Masi AT (1988) Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 15(6):894-898 (Jun)
23. Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750-755
24. Reveille JD, Solomon DH, The American College of Rheumatology Ad hoc Committee on Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: Anticentromere, Sl-70 and nucleolar antibodies. Arthritis Rheum 49(3):399-412
25. Arnett F, Reveille JD, Goldstein R et al (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): An immunogenetic, serological and clinical analysis. Arthritis Rheum 39:1151-1160
26. Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 44:1212-1216
27. Cepeda EJ, Reveille JD (2004) Antibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. Curr Opin Rheumatol 16:723-732
28. Fritzler MJ (2006) Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 15:422-427
29. Steen VD, Powell DL (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with progressive systemic sclerosis. Arthritis Rheum 31:196-203
30. Bernstein RM, Steigerwald JC, Tan EM (1982) Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Rheumatol 48(1):43-51
31. Satiago M, Baron M, Burlingame RW et al (2007) Antibodies to RNA polymerase III in systemic sclerosis as detected by an ELISA. Arthritis Rheum (Arthritis Care and Research) (submitted for publication, January 2007)
32. Tormey VJ, Bunn CC, Denton CP et al (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40(10):1157-1162
33. Brown GE, O'Leary PA (1925) Skin capillaries in scleroderma. Arch Intern Med 36:73-88
34. Maricq HR, LeRoy EC (1973) Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum 16:619-628
35. Cutolo M, Pizzorni C, Sulli A (2005) Capillaroscopy. Best Pract Res Clin Rheumatol 19(3):437-452
36. Maricq HR (1981) Widefield capillary microscopy: Technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 24(9):1159-1165
37. Cutolo M, Sulli A, Pizzorni C et al (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155-160
38. Nagy Z, Czirjak L (2004) Nailfold digital capillaroscopy in 447 patients with connectiv tissue disease ad Raynaud's diseases. J Eur Dermatol Acad Venereol 18:62-68
39. Cutolo M, Pizzorni C, Tuccio A et al (2004) Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 43:719-726
40. Anderson ME, Allen PD, Moore T et al (2005) Computerized nailfold video capillaroscopy - a new tool for assessment of Rayaud's phenomenon. J Rheumatol 32:841-848
41. Bergman R, Sharony L, Schapira D et al (2003) The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 139:1027-1030
42. Baron M, Bell M, Bookman A et al (2007) Office capillaroscopy in systemic sclerosis. Clin Rheum (in press)
43. Capusan I (1972) Curzio's case of scleroderma (letter). Ann Intern Med 76(1):146
44. Barnett AJ (1978) Scleroderma (progressive systemic sclerosis): Progress and course based on a personal series of 118 patients. Med J Aust 2(4):129-134
45. Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22(2):130-140
46. Akesson A, Wollheim FA (1989) Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 28:281-286
47. Vayssairat M, Baudot N, Abuaf N et al (1992) Long-term follow-up study of 164 patients with definite systemic sclerosis: Classification considerations. Clin Rheum 11(3):356-363
48. Lonzetti LS, Joyal F, Raynauld JP et al (2001) Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 44(3):735-736 (Mar)